Acute methemoglobinemia is a life-threatening disorder caused by chemicals and drugs, but rarely by chemotherapeutic agents. A high index of suspicion should be employed in patients with cyanosis out of proportion to their cardiopulmonary status. Prompt diagnosis, removal of toxic drugs, and treatment can quickly reverse methemoglobin (MetHb) formation. We report a case of methemoglobinemia in which cyclophosphamide is the likely etiologic toxic agent.
A 42-year-old Caucasian woman with metastatic carcinoma of the breast was admitted to the hospital for highdose chemotherapy followed by autologous stem cell support using the previously published STAMP-I protocol 1 consisting of cyclophosphamide 1.875 mg/m 2 /day i.v. and cisplatin 55 mg/m 2 /day i.v. day -6 to day À4. Her concomitant medications included ondansetron, diphenhydramine, fluticasone inhaler, lorazepam as needed, magnesium sulfate and continuous metoclopramide infusion through the admission course as per protocol. There was no significant past medical history of diabetes or cardiopulmonary disease. Before receiving BCNU on day À3, the patient complained of fatigue, headache, and lightheadedness. On examination, the following were observed: BP 124/64 mmHg, a pulse of 105, temperature of 98.7, mild cyanosis in the face and the lips, and mild basilar crackles in the lungs. She was hypoxic by pulse oximetry and required oxygen supplementation. The patient had 5 kg weight gain, and diuresis was begun with furosemide. She had a transient improvement, but her oxygen requirement continued to increase subsequently and was becoming hypoxic on 100% non-rebreather mask with pulse oximetry around 85-90%. An arterial blood gas evaluation on 100% FiO 2 revealed pH of 7.37, PaO 2 of 201 mmHg, PaCO 2 of 28.4 mmHg, HCO 3 of 17 mmol/l, oxygen saturation of 87%, and serum bicarbonate of 18 mmol/l. CO-oximetry on arterial blood showed carboxyhemoglobin (COHb) and MetHb concentrations of 0.2 and 10.7%, respectively. Her hemoglobin count was 11.3 gm/dl. Methylene blue was administered as 90 mg (1 mg/kg) i.v. infusion over 5 min. At 1 h following the administration of methylene blue, the MetHb level decreased to 3.2%. Repeat arterial blood gases confirmed the improvement in the oxygen saturation. On the same day, the patient received carmustine (BCNU) 600 mg/m 2 as per protocol without any further complications, and was discharged as per protocol 3 days later, uneventfully. The MetHb level 24 h after the methylene blue injection was 1.7%. Hemoglobin electrophoresis showed no hemoglobin M. Cytochrome b5 reductase (NADH diaphorase) of red cells was 10.3 IU/g HB (normal 10-19.4).
Methehemoglobin is an altered state of hemoglobin in which ferrous irons of heme are oxidized to the ferric state. In the normal physiologic state, MetHb is produced, but mechanisms exist to keep the level below 1%. The ferric hemes of MetHb are unable to bind oxygen. In addition, the oxygen affinity of residual ferrous hemes is increased, resulting in shifting of the oxygen dissociation curve to the left. 2 Methemoglobinemia may arise as a result of a genetic defect in red blood cell metabolism or hemoglobin structure, or it may be acquired following exposure to various oxidant drugs or toxins. 3 Symptoms from methemoglobinemia vary according to the level of MetHb and underlying medical problems, especially in patients with lung disease. Methemoglobinemia may be clinically suspected by the presence of clinical cyanosis in the face of a normal arterial PO 2 as obtained by arterial blood gases. Pulse oximetry is neither accurate in making the diagnosis nor helpful in monitoring oxygen saturation in the presence of MetHb. Since MetHb has a spectrum of light absorption close to oxyhemoglobin (630 vs 660 nm), the diagnosis of methemoglobinemia requires a spectrophotometer to test blood for MetHb, COHb, oxyhemoglobin, and deoxyemoglobin (CO oximetry). 4 The treatment of acquired methemoglobinemia depends on the clinical settings and the level of the MetHb. Suspected offending agents should be stopped. In symptomatic patients or patients with high levels of MetHb, methylene blue should be infused slowly, but should not exceed a cumulative dose of 7 mg/kg. Methylene blue at high doses can induce hemolysis. Cyclophosphamide administration during the 3 days prior to the diagnosis was the suspected offending drug causing methemoglobinemia. This patient continued to receive metoclopramide, an agent implicated to cause methemoglobinemia, after treatment without recurrence of methemoglobinemia, suggesting that cyclophosphamide was the likely culprit, although an interaction between the two drugs cannot be fully excluded. The red cell MetHb reductase was normal, which excluded the congenital deficiency of this enzyme.
Cyclophosphamide requires metabolic activation to exert its anticancer activity, as demonstrated by the lack of such activity of the parent compound in vitro. 5 It undergoes transformation by the cytochrome P450 microsomal system in the liver to 4-hydroxycyclophosphamide, and by other intracellular metabolic pathways to the final cytotoxic metabolites, phosphomaramide mustard and acrolein. The exact mechanism of cyclophosphamide-induced methemoglobinemia is not well discerned particularly in the highdose setting. Glutathione depletion would be a plausible mechanism, since Gurtoo et al 6 have shown that glutathione and other sulfhydryl-containing compounds can protect against cyclophosphamide toxicity. High doses of cyclophosphamide are known to cause cardiac toxicity through the proposed glutathione depletion mechanism as shown by Freidman et al.
Generally, chemotherapeutic agents do not commonly cause methemoglobinemia. Hadjiliadis et al 8 reported a case of methemoglobinemia induced by ifosfamide, a compound related to cyclophosphamide in structure and metabolic pathway. They proposed that 4-thioifosfamide, a deactivated ifosfamide metabolite, reacts with glutathione depleting the cell antioxidant stores. 8 A review of the literature showed two cases of methemoglobinemia induced by trophosphamide, an oral cytotoxic agent derivative of cyclophosphamide. 9 However, no cases of platinum-induced methemoglobinemia have been reported.
We propose the mechanism of cyclophosphamide-induced methemoglobinemia to resemble the one reported on the ifosfamide case, since they share similar chemical compounds, metabolic pathways, and toxicities.
Physicians treating patients with chemotherapeutic agents should be aware of this potential life-threatening complication and at the same time, cyclophosphamide should be considered as a potential cause of methemoglobinemia in susceptible patients. 
